An observational study in Hepatitis B, Chronic, sponsored by Yaşar Bayındır, MD. Recruiting at 10 sites in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Yaşar Bayındır, MD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Hepatitis B, Chronic with a site in Turkey — 1 open to participants now, 1 under way, none of them phase 3. Hepatitis B, Chronic · Turkey.
Among the 31 studies in Hepatitis B, Chronic with a site in Turkey, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 30th registered.
899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 31 studies in Hepatitis B, Chronic with a site in Turkey is open now.
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 400 across 209 observational studies indexed under Hepatitis B, Chronic.
Median enrollment 208 across the 24 interventional studies, 516 across the 6 observational. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 31 have an industry lead sponsor. The 10 most frequent:
Yaşar Bayındır, MD is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Yaşar Bayındır, MD has 2 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies in Hepatitis B, Chronic with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07459426Yaşar Bayındır, MDEntecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study) | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Hepatitis B, Chronic with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage.
Some older antiviral medications, such as lamivudine, can lead to the development of viral resistance. This means the virus changes in a way that makes certain treatments less effective. Even though newer drugs like entecavir are stronger and more resistant to these changes, previous exposure to lamivudine may increase the risk of developing additional resistance mutations.
By analyzing viral genetic material from blood samples using advanced sequencing technology, this research will help improve understanding of antiviral resistance patterns in patients with chronic hepatitis B in Turkey and may support better treatment decisions in the future.
Hypothesis
Sample size: 700 estimated participants
Pre-existing lamivudine-induced resistance mutations create a genetic background that facilitates the emergence of secondary entecavir resistance mutations, even in patients currently receiving tenofovir-based therapy.
Investigators further hypothesize that peripheral blood-derived cccDNA sequencing can serve as a minimally invasive method to characterize transmitted and acquired resistance mutation profiles in chronic HBV infection.
Clinical Significance Chronic hepatitis B management relies on long-term antiviral therapy, and resistance-associated mutations significantly influence treatment success and future therapeutic strategies.
Although entecavir has a high genetic barrier, prior lamivudine exposure may predispose patients to secondary resistance mutations, potentially compromising antiviral efficacy. However, the prevalence and distribution of such mutations in the Turkish HBV population remain insufficiently characterized
This study will provide:
The findings may contribute to optimizing antiviral selection strategies, guiding individualized treatment decisions, and informing national hepatitis B management policies.
This study will provide national-level data on entecavir resistance mutations in Turkey.
It may support individualized antiviral selection and contribute to national HBV management strategies.
Adult (≥18 years) HBsAg-positive patients with a documented history of lamivudine therapy for ≥6 months who were subsequently switched to tenofovir-based therapy (ADV, TDF, or TAF) and have not received entecavir or telbivudine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with insufficient sample volume or inadequate DNA quality for sequencing will be excluded from final analysis.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult (≥18 years) HBsAg-positive patients with HBV-DNA \>2,000 IU/mL who have not received prior nucleos(t)ide analogue therapy.
Diagnostic Test: Viral genetic material from blood samples using advanced sequencing technology
Adult (≥18 years) HBsAg-positive patients with a documented history of lamivudine therapy for ≥6 months who were subsequently switched to tenofovir-based therapy (ADV, TDF, or TAF) and have not received entecavir or telbivudine.
Diagnostic Test: Viral genetic material from blood samples using advanced sequencing technology
No intervention
Prevalence of entecavir resistance-associated mutations in the HBV polymerase/RT region detected by Oxford Nanopore sequencing.
Detection of entecavir resistance-associated mutations (T184, S202, M250), with or without lamivudine resistance background mutations (L180M, M204V/I), in the HBV polymerase/RT region by Oxford Nanopore sequencing of peripheral blood-derived cccDNA. Mutations will be reported if detected at an allele frequency ≥5%.
Time frame: March 15th, 2026-March 15th, 2027
Comparison of mutations between two groups.
Comparison of mutation frequency between treatment-naïve and lamivudine-experienced patients. Comparison of mutation frequency between treatment-naïve and lamivudine-experienced patients. Comparison of mutation frequency between treatment-naïve and lamivudine-experienced patients.
Time frame: March 15th, 2026-March 15th, 2027
Association between HBV-DNA level and resistance-associated mutation presence.
Association between HBV-DNA level and resistance-associated mutation presence in all groups.
Time frame: March 15th, 2026-March 15th, 2027
Duration of lamivudine exposure and secondary mutations.
Association between duration of lamivudine exposure and secondary mutations.
Time frame: March 15th, 2026-March 15th, 2027
Classical lamivudine resistance mutations and their co-occurrence with ETV resistance mutations.
Detection of classical lamivudine resistance mutations (M204V/I, L180M) and their co-occurrence with ETV resistance mutations.
Time frame: March 15th, 2026-March 15th, 2027
Plan to share: No — Prevalence of entecavir resistance-associated mutations in the HBV polymerase/RT region detected by Oxford Nanopore sequencing.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2026 → Dec 2026 and completion Mar 2027 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yaşar Bayındır, MD